Urologists and other physicians who treat Medicare patients have been given a short reprieve from the across-the-board 10.1% reimbursement cut that was scheduled for Jan. 1, and have even received a little bit of a raise.
Dr. Schuster highlights the FDA approval of imaging agent flotufolastat F 18 in prostate cancer
June 22nd 2023"We're excited that the FDA approval of this radiotracer gives us yet more tools at our disposal to diagnose prostate cancer in all its forms, from early to late in the disease process," says David M. Schuster, MD, FACR.
2 Clarke Drive
Cranbury, NJ 08512